Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL1932986

CNC.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.43
CA1 P00915 2/20 0.43
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA7 P43166 1/20 0.37
CA13 Q8N1Q1 1/20 0.37
F2 P00734 2/20 0.36
PRSS1 P07477 2/20 0.36
PRSS2 P07478 2/20 0.36
PRSS3 P35030 2/20 0.36
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
EPHX1 P07099 1/20 0.34
CA5A P35218 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
MAPK1 P28482 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL2240490 0.90 CA2 (0.45) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL1750663 0.90 CA2 (0.45) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL30662099 0.89 ALDH1A1 (0.47) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL28271598 0.87 CA2 (0.43) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL9460589 0.86 ALDH1A1 (0.45) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL28243370 0.86 ALDH1A1 (0.45) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL27964313 0.86 ALDH1A1 (0.45) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL2290380 0.86 ALDH1A1 (0.45) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL39465 0.86 ALDH1A1 (0.50) CA2CA1ALDH1A1L3MBTL1CA7
Trifluoromethanesulfonic Acid SCHEMBL295 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366559-A1 METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS SUMITOMO PHARMA AMERICA, INC. (US) 2024-11-07 US claimed
EP-4736951-A2 (S)-(4,5-DIHYDRO-7H-THIENO[2,3-C]PYRAN-7-YL)-N-METHYLMETHANAMINE FOR TREATING, PREVENTING AND/OR MANAGING A NEUROLOGICAL AND/OR PSYCHIATRIC DISORDER Sumitomo Pharma America, Inc. (US) 2026-05-06 EP disclosed
WO-2025009867-A1 METHOD FOR MANUFACTURING CONDUCTIVE ACRYLIC FIBER AND CONDUCTIVE ACRYLIC FIBER MANUFACTURED THEREBY 다나눔패션 주식회사 2025-01-09 WO disclosed
US-20240366559-A1 METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS SUMITOMO PHARMA AMERICA, INC. (US) 2024-11-07 US disclosed
WO-2023204304-A1 METHOD FOR PRODUCING 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE 大鵬薬品工業株式会社 2023-10-26 WO disclosed
US-11738002-B2 Methods of treating neurological and psychiatric disorders SUNOVION PHARMACEUTICALS INC. (US) 2023-08-29 US disclosed
EP-4135690-A1 (S)-(4,5-DIHYDRO-7H-THIENO[2,3-C]PYRAN-7-YL)-N-METHYLMETHANAMINE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS Sunovion Pharmaceuticals Inc. (US) 2023-02-22 EP disclosed
CN-115407606-A Composition for photoresist underlayer 罗门哈斯电子材料韩国有限公司 2022-11-29 CN disclosed
CN-113126432-A Coating composition for photoresist underlayer 罗门哈斯电子材料韩国有限公司 2021-07-16 CN disclosed
US-9289381-B2 Stabilization and storage of biological pharmaceutical compositions THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) 2016-03-22 US disclosed
US-20120230944-A1 STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-09-13 US disclosed
WO-2011069037-A2 STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) 2011-06-09 WO disclosed
US-20070048660-A1 Resist composition, method for forming resist pattern, semiconductor device and method for manufacturing thereof FUJITSU LIMITED (JP) 2007-03-01 US disclosed
EP-1757983-A1 Resist composition, method for forming resist pattern, semiconductor device and method for manufacturing thereof Fujitsu Ltd. (JP) 2007-02-28 EP disclosed
EP-0170288-A2 Additive for improving weathering resistance and decreasing viscosity of high solids coatings UNION CARBIDE CORPORATION (US) 1986-02-05 EP disclosed
US-4556693-A COPOLYMER OF HYDROXY (METH) ACRYLATE AND POLYCAPROLACTONE HEXOL UNION CARBIDE CORPORATION (US) 1985-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11738002-B2 Methods of treating neurological and psychiatric disorders GRIN2A, SLC6A3, GRIN2C CA2 2748/4885CA1 2244/4885ALDH1A1 1649/4885
US-20240366559-A1 METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS GRIN2A, SLC6A3, GRIN2C CA2 2748/4885CA1 2244/4885ALDH1A1 1649/4885
US-20120230944-A1 STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS IL2, IL2RA, IL36G CA2 1853/4885CA1 4068/4885ALDH1A1 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.